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Clinical PerspectiveWhat Is New?For the first time, this study revealed the high expression of circular RNA (hsa_circRNA_025016) in plasma before surgery predicted new‐onset atrial fibrillation after isolated off‐pump coronary artery bypass grafting.What Are the Clinical Implications?The present study demonstrates that this plasma hsa_circ_025016 holds potential as a biomarker for the prediction of postoperative atrial fibrillation and could enable us to more accurately target patients who are at risk and thereby improve the effects of prophylactic treatments.

Introduction {#jah32831-sec-0008}
============

Pervasive expression of circular RNAs (circRNAs) in highly divergent eukaryotes was discovered in 2012.[1](#jah32831-bib-0001){ref-type="ref"} Recently, thousands of human circRNAs have been identified using molecular biology strategies coupled with new bioinformatic approaches.[2](#jah32831-bib-0002){ref-type="ref"} CircRNAs are expressed in tissue‐specific and developmental stage‐dependent manners.[3](#jah32831-bib-0003){ref-type="ref"} The dysregulations of circRNAs contribute to many diseases because they act as microRNA target decoys, RNA binding protein sponges, and transcriptional regulators.[4](#jah32831-bib-0004){ref-type="ref"} Additionally, circRNAs are highly stable because of a resistance to debranching enzymes and RNA exonucleases. Therefore, circRNAs possess distinct advantages and may be useful as new biomarkers for diagnosis, prognosis, and therapeutic response prediction.[2](#jah32831-bib-0002){ref-type="ref"}

Postoperative atrial fibrillation (PoAF) is one of the most common complications following coronary artery bypass grafting (CABG).[5](#jah32831-bib-0005){ref-type="ref"} The reported incidences of atrial fibrillation (AF) after CABG range from 15% to 50%. PoAF is associated with significantly increased morbidity, mortality, and total treatment costs.[6](#jah32831-bib-0006){ref-type="ref"} Although potential biomarkers of PoAF, such as mtDNA copy numbers and microRNAs,[7](#jah32831-bib-0007){ref-type="ref"}, [8](#jah32831-bib-0008){ref-type="ref"} have been actively researched, the diagnostic use of plasma circRNAs for PoAF has never been investigated. Our study screened the plasma circRNAs expression profiles (13 617 circRNAs) of patients with and without PoAF. The selected circRNAs that were found to be associated with PoAF were then tested in 2 additional independent populations of patients who underwent CABG.

Methods {#jah32831-sec-0009}
=======

Because of privacy, the data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.

Study Design and Patients {#jah32831-sec-0010}
-------------------------

Seven hundred sixty‐nine blood samples were collected from the Department of Cardiovascular Surgery of the General Hospital of Shenyang Military Area Command from March 1, 2015 to June 31, 2016. All patients underwent off‐pump CABG. The inclusion criteria, surgical procedure, and monitoring of AF onset were performed as described previously.[8](#jah32831-bib-0008){ref-type="ref"} Patients' blood samples were collected within 1 week before surgery. Blood samples from 15 healthy donors were collected from the Health Examination Center of the General Hospital of Shenyang Military Area Command. All samples in this study were collected after informed consent was obtained from the participants, and all procedures were conducted according to an established protocol that was approved by the Ethics Committee of the General Hospital of Shenyang Military Area Command. The samples were allocated to 3 phases in chronological order (Figure [1](#jah32831-fig-0001){ref-type="fig"}A).

![Representation of the workflow of the screening and validation of the circular RNAs (circRNAs) in various populations with and without postoperative atrial fibrillation (PoAF). A, A total of 769 samples were collected from patients who underwent isolated off‐pump coronary artery bypass grafting. This approach identified that hsa_circRNA_025016 predicted PoAF. B, Hierarchical clustering based on the levels of circulating circRNAs in patients with and without PoAF. C, The relationships between circulating circRNAs and PoAF. The data are presented as the odds ratios and 95% confidence intervals (CI) per 1 SD. D, Showing the relationship between hsa_circRNA_404686 and hsa_circRNA_025016. CABG indicates coronary artery bypass; CI, confidence interval; FDR, false discovery rate; qPCR, quantitative polymerase chain reaction.](JAH3-7-e006642-g001){#jah32831-fig-0001}

Discovery Phase {#jah32831-sec-0011}
---------------

Potential associations between detectable circRNAs in EDTA‐plasma and the onset of PoAF were analyzed in a retrospective case‐controlled clinical trial ([ClinicalTrials.gov](http://ClinicalTrials.gov), NCT02807532). Overall, 120 patients who underwent off‐pump CABG were recruited to this study, and the incidence of PoAF was 16.7% (20/120). In this cohort, 15 patients who developed PoAF were selected as case subjects, and 15 non‐PoAF patients with matched characteristics (ie, age, sex, smoking, left atrial diameter, left ventricle end‐diastolic volume, and the use of statins before surgery) were selected as control subjects. A circRNA microarray was used to screen 13 617 human circRNAs in these 15 pairs of case--control samples. The microarray information was submitted to the Gene Expression Omnibus under the accession number [GSE97455](GSE97455).

Training Phase {#jah32831-sec-0012}
--------------

The 9 circRNAs discovered via the microarray analyses were first tested by quantitative real‐time polymerase chain reaction in an independent cohort of plasma samples from 365 consecutive participants who were recruited from June 2015 to December 2015. Of these circRNAs, 6 were consistently amplified in all individual samples. Two circRNAs were differentially expressed between the PoAF and non‐PoAF groups in this cohort. One of the 2 circRNAs exhibited the greatest association with PoAF.

Validation Phase {#jah32831-sec-0013}
----------------

The optimal mean cutoff generated from the training phase was applied to an independent cohort of 284 consecutive participants who were included from January 2016 to June 2016 to evaluate the diagnostic performance of the circRNA (hsa_circRNA_025016).

Plasma Preparation and RNA Isolation {#jah32831-sec-0014}
------------------------------------

For the plasma preparation, peripheral blood (3--4 mL) was drawn into EDTA tubes. Within 30 minutes, each tube was subjected to centrifugation at 1000 g for 15 minutes. Next, 1 mL plasma was transferred to a 1.5‐mL Eppendorf tube and centrifuged at 11 000 g for 10 minutes to pellet any remaining cellular debris. Each EDTA tube can isolate nearly 2 mL plasma. Subsequently, the supernatants were transferred to fresh tubes and stored at −80°C. For the plasma samples, the total RNA was extracted using TRIzol LS according to the instructions from the manufacturer (Thermo Scientific, Waltham, MA). The concentrations were quantified with a NanoDrop 1000 Spectrophotometer (NanoDrop Technologies, Waltham, MA). The integrity of the RNA was assessed by electrophoresis on a denaturing agarose gel.

Microarray Analysis {#jah32831-sec-0015}
-------------------

The sample preparation and microarray hybridization were performed based on the Arraystar\'s standard protocols. The microarray contained probes for 13 617 human circRNAs. Briefly, the total RNAs were digested with Rnase R (Epicentre, Madison, WI) to remove linear RNAs and enrich the circRNAs. Then, the enriched circRNAs were amplified and transcribed into fluorescent cRNA utilizing a random priming method (Arraystar Super RNA Labeling Kit; Arraystar, Rockville, MD). The labeled cRNAs were hybridized onto the Arraystar Human circRNA Array (8×15 K). After washing the slides, the arrays were scanned with an Agilent Scanner G2505C (Arraystar, Rockville, MD).

Quantitative Real‐Time Polymerase Chain Reaction {#jah32831-sec-0016}
------------------------------------------------

To test the candidate circRNAs that were acquired on the microarrays, circRNA detection was next validated by real‐time polymerase chain reaction. For this purpose, the isolated RNAs were reverse transcribed with random primers. Specific circRNAs were amplified using the primers listed in Table [1](#jah32831-tbl-0001){ref-type="table-wrap"}. The assays for the following circRNAs were first performed on 365 samples from 9 candidates: hsa_circRNA_404686, hsa_circRNA_000367, hsa_circRNA_001729, hsa_circRNA_100790, hsa_circRNA_104270, hsa_circRNA_030162, hsa_circRNA_100789, hsa_circRNA_025016, and hsa_circRNA_102049. The expression level of 18S RNA was used as a stable endogenous control for normalization. All assays were performed in triplicate.

###### 

Sequence of PCR Primers Used in This Study

  -------------------- ------------------------------ --------------------------------
  18s                  F:5′ CGGCTACCACATCCAAGGAA3′    R :5′ GCTGGAATTACCGCGGCT3′
  hsa_circRNA_404686   F:5′CTCAGAACAAGAGCGTCCATT3′    R:5′AAGGCTGATGAAGAGGGAGG3′
  hsa_circRNA_000367   F:5′CATCGAAGACTGGCGTGAAAC3′    R:5′CAGTTACAGAATCGTATGGAATGG3′
  hsa_circRNA_001729   F:5′AGACCATTCCATTCTGGCTACA3′   R:5′TACCCCCTGGCTGCTGTGT3′
  hsa_circRNA_100790   F:5′AAGTATTTCAGGCTGGGACAAG3′   R:5′TGTACCCCTCACTTGTGGATG3′
  hsa_circRNA_030162   F:5′TGGGACTGATGTCATCTTGAGC3′   R:5′ATTTCCACCAATGAGCGAGTC3′
  hsa_circRNA_100789   F:5′TGTAAATGCAGCTCCATTCCAA3′   R:5′ACCTGTGTCGCTTCTGGTTGTA3′
  hsa_circRNA_025016   F:5′GCCTTAGCGATCTATATTCCCT3′   R:5′GCATTGGCATTCATGTTGG3′
  hsa_circRNA_104270   F:5′CGACAGCGGGTCTACTCACTCT3′   R:5′GGTACTTCCCACAAATCCTTGC3′
  hsa_circRNA_102049   F:5′GCATCTACCCTGCTGAACCT3′     R:5′CATTTCTTCTTGAGCAGTCCAG3′
  -------------------- ------------------------------ --------------------------------

PCR indicates polymerase chain reaction.

Annotation and Functional Prediction for hsa_circ_025016 {#jah32831-sec-0017}
--------------------------------------------------------

To explore the targeted miRNA profile, the miRNA support vector regression algorithm was used to score and rank the efficiencies of the predicted miRNA targets. Hsa_circ_025016 was used as a seed to enrich a circRNA‐miRNA‐gene network according to analyses with TargetScan (<http://www.targetscan.org/>) combined with miRanda (<http://www.microrna.org/>). The biological pathways were defined with the Kyoto Encyclopedia of Genes and Genomes.

Statistical Analysis {#jah32831-sec-0018}
--------------------

In the discovery phase, paired *t* tests were performed to identify the circRNAs that were differentially expressed in the PoAF and non‐PoAF groups. Multiple comparison corrections were performed by calculating the Benjamini‐Hochberg false discovery rate. Filtering of all the circRNAs with fold changes ≥4 and false discovery rate values \<0.05 yielded 9 circRNAs that were differentially expressed between the PoAF and non‐PoAF groups. The training cohort (365) was divided into training data and validation data via 10‐fold cross‐validation method using the R package caret. The cutoff value, sensitivity, specificity, and area under the receiver operating characteristic curve of each training data were estimated by roc () function of R package *Daim*. The sensitivity and specificity of each validation data were calculated based on the corresponding cutoff of each training data, while the sensitivity and specificity of validation cohort (284) were calculated based on the mean cutoff of training data, both with a diagnostic test 4‐fold table. Based on the expression of hsa_circ_025016 and the incidence of PoAF (16.7%) in discovery phage, at an α level of 5% and a power of 90%, 15 patients of PoAF and 75 patients of no‐PoAF would be required. Therefore, sample size in training and validation cohorts was sufficient. All statistical calculations were performed using SPSS 18.0 software (IBM, Chicago, IL). In all statistical analyses, the circRNAs levels were log‐transformed using the base 2 logarithm to account for the skewnesses of their distributions. Continuous variables were compared using unpaired Student *t* tests. Categorical variables were compared using χ^2^ tests.[8](#jah32831-bib-0008){ref-type="ref"} A logistic regression was used to select the diagnostic circRNA markers based on the training data set. *P*\<0.05 was considered significant in all comparisons.

Results {#jah32831-sec-0019}
=======

Levels of Circulating circRNAs Were Altered in Patients Who Developed PoAF {#jah32831-sec-0020}
--------------------------------------------------------------------------

The characteristics of the 120 patients included in this study are summarized in Table [2](#jah32831-tbl-0002){ref-type="table-wrap"}. Because of the relatively small size of the cohort and low incidence of AF after surgery, none of the characteristics were found to be associated with PoAF. In consideration of our previous study and other clinical studies, patients with and without PoAF were matched for age, sex, smoking, left atrial diameter, left ventricle end‐diastolic volume, and the use of statins before surgery. The characteristics of the 30 patients are presented in Table [3](#jah32831-tbl-0003){ref-type="table-wrap"}. In an attempt to study alterations in the circulating circRNAs in the PoAF patients, microarray analyses were performed on the RNA from the plasma of these 30 patients.

###### 

Demographic and Clinical Characteristics by Presence of PoAF in Discovery Phase

  Characteristics                 PoAF Group n=20   No PoAF Group n=100   *P* Value
  ------------------------------- ----------------- --------------------- -----------
  Sex (male/female)               15/5              84/16                 0.519
  Age, y                          61.50±6.94        62.01±7.23            0.772
  BMI, kg/m^2^                    24.10±2.23        24.97±2.78            0.189
  Smoking, %                      16 (80.0)         62 (62.0)             0.123
  Heart rate, beats/min           73.75±8.76        71.37±10.34           0.291
  NYHA III--IV, %                 4 (20.0)          17 (17.0)             0.747
  Hypertension, %                 14 (70.0)         60 (60.0)             0.401
  DM, %                           8 (40.0)          41 (41.0)             0.934
  Pre--myocardial infarction, %   9 (45.0)          54 (54.0)             0.462
  Blood glucose, mmol/L           6.10±2.79         6.67±5.32             0.490
  Cholesterol, mmol/L             4.33±0.99         4.31±0.92             0.929
  Triglyceride, mmol/L            1.94±0.62         2.00±1.31             0.754
  LDL, mmol/L                     2.74±0.84         2.50±0.83             0.253
  HDL, mmol/L                     0.92±0.11         0.94±0.16             0.499
  Creatinine, μmol/L              74.03±11.96       72.59±14.98           0.687
  CKMB, U/L                       12.55±9.26        13.06±24.22           0.873
  cTNT, ng/mL                     0.13±0.27         0.10±0.46             0.695
  EF                              0.54±0.06         0.55±0.05             0.419
  LAD, mm                         38.70±5.43        36.22±4.54            0.067
  PASP, mm Hg                     35.85±11.97       33.89±6.09            0.483
  LVEDV, mL                       122.60±46.23      110.36±36.48          0.262
  β‐Blockers, %                   18 (90.0)         92 (92.0)             0.882
  ACEI, %                         8 (40.0)          46 (46.0)             0.622
  CCB, %                          11 (55.0)         51 (51.0)             0.744
  Statins, %                      11 (55.0)         71 (71.0)             0.160

Data presented as mean±SD or as a ratio. ACEI indicates angiotensin‐converting enzyme inhibitor; BMI, body mass index; CCB, calcium channel blocker; CKMB, creatine kinase MB; cTNT, cardiac troponin T; DM, diabetes mellitus; EF, ejection fraction; HDL, high‐density lipoprotein; LAD, left atrial diameter; LDL, low‐density lipoprotein; LVEDV, left ventricle end‐diastolic volume; NYHA, New York Heart Association; PASP, pulmonary arterial systolic pressure; PoAF, postoperative atrial fibrillation.

###### 

Demographic and Clinical Characteristics by Presence of PoAF in 15 Paired Patients

  Characteristics                 PoAF Group n=15   No PoAF Group n=15   *P* Value
  ------------------------------- ----------------- -------------------- -----------
  Sex (male/female)               11/4              11/4                 1.000
  Age, y                          61.00±10.05       61.13±8.50           0.969
  BMI, kg/m^2^                    24.30±3.56        24.37±2.70           0.934
  Smoking, %                      12 (80.0)         12 (80.0)            1.000
  Heart rate, beats/min           74.4±7.67         75.4±10.01           0.762
  NYHA III--IV, %                 0 (0)             0 (0)                1.000
  Hypertension, %                 13 (86.7)         13 (86.7)            1.000
  DM, %                           6 (40.0)          6 (40.0)             1.000
  Pre--myocardial infarction, %   8 (46.7)          7 (53.3)             0.715
  Blood glucose, mmol/L           6.12±1.81         6.02±1.58            0.820
  Cholesterol, mmol/L             4.30±1.09         4.42±1.08            0.760
  Triglyceride, mmol/L            1.63±0.97         1.62±0.60            0.978
  LDL, mmol/L                     2.65±1.12         2.838±0.97           0.692
  HDL, mmol/L                     0.89±0.18         0.92±0.19            0.752
  Creatinine, μmol/L              73.14±12.62       75.18±18.91          0.731
  EF                              0.54±0.06         0.55±0.07            0.548
  LAD, mm                         38.70±5.34        38.5±5.28            0.883
  PASP, mm Hg                     35.8±9.80         36.8±6.67            0.640
  LVEDV, mL                       120.6±40.80       121.0±35.6           0.967
  β‐Blockers, %                   14 (93.0)         14 (93.0)            1.000
  ACEI, %                         7 (46.7)          7 (46.7)             1.000
  CCB, %                          9 (60.0)          9 (60.0)             1.000
  Statins, %                      8 (53.3)          8 (53.3)             1.000

Data presented as mean±SD or as a ratio. ACEI indicates angiotensin‐converting enzyme inhibitor; BMI, body mass index; CCB, calcium channel blocker; DM, diabetes mellitus; EF, ejection fraction; HDL, high‐density lipoprotein; LAD, left atrial diameter; LDL, low‐density lipoprotein; LVEDV, left ventricle end‐diastolic volume; NYHA, New York Heart Association; PASP, pulmonary arterial systolic pressure; PoAF, postoperative atrial fibrillation.

As illustrated in Figure [1](#jah32831-fig-0001){ref-type="fig"}B, 31 circRNAs were specifically dysregulated (24 circRNAs were upregulated, and 7 circRNAs were downregulated with the fold changes ≥2 and FDR (false discovery rate) \<0.05, Table [4](#jah32831-tbl-0004){ref-type="table-wrap"}) in patients with PoAF compared with who did not develop AF. Filtering of all of the differentially expressed circRNAs for changes ≥4‐fold yielded 9 circRNA candidates (hsa_circRNA_404686, hsa_circRNA_000367, hsa_circRNA_001729, hsa_circRNA_100790, hsa_circRNA_104270, hsa_circRNA_030162, hsa_circRNA_100789, hsa_circRNA_025016, and hsa_circRNA_102049) for further testing via quantitative real‐time polymerase chain reaction.

###### 

Dysregulated circRNAs in Patients With PoAF Compared to Who Did Not Develop Af

  *P* Value                FDR           FC (abs)     Gene Symbol   circRNA              Chrom
  ------------------------ ------------- ------------ ------------- -------------------- -------
  Upregulated circRNAs                                                                   
  5.24085E‐06              0.003754004   13.6095532   GPR137B       hsa_circRNA_404686   chr1
  7.93744E‐06              0.004796739   12.1794537   SIAE          hsa_circRNA_000367   chr11
  0.000591413              0.035205611   5.3908059    ZNF646        hsa_circRNA_001729   chr16
  4.69587E‐05              0.010234685   4.5960716    CAPRIN1       hsa_circRNA_100790   chr11
  1.88183E‐05              0.007525187   4.3381437    FAM120B       hsa_circRNA_104270   chr6
  0.000196313              0.021978096   4.1453242    TPT1          hsa_circRNA_030162   chr13
  6.79548E‐05              0.01284492    4.1117028    CAPRIN1       hsa_circRNA_100789   chr11
  0.000257758              0.028857183   4.1002143    CACNA1C       hsa_circRNA_025016   chr12
  4.64186E‐05              0.010234685   4.0394495    TADA2A        hsa_circRNA_102049   chr17
  6.88132E‐05              0.01284492    3.6851138    CAPRIN1       hsa_circRNA_100787   chr11
  4.5274E‐05               0.010234685   3.6084518    TADA2A        hsa_circRNA_405571   chr17
  0.001104905              0.047082396   2.7738857    TADA2A        hsa_circRNA_102051   chr17
  0.000153536              0.020012406   2.4205083    RPL11         hsa_circRNA_010884   chr1
  0.000732237              0.038163645   2.4201776    MTO1          hsa_circRNA_104135   chr6
  0.000298757              0.026560557   2.3774407    RPS17L        hsa_circRNA_036567   chr15
  4.04835E‐05              0.010155248   2.3613541    EEF1A1        hsa_circRNA_077007   chr6
  0.000141757              0.019506189   2.3492044    TRAPPC4       hsa_circRNA_400850   chr11
  6.84306E‐05              0.01284492    2.2456712    LYST          hsa_circRNA_005899   chr1
  0.000037955              0.009704072   2.2092508    IFI30         hsa_circRNA_102484   chr19
  3.8865E‐07               0.002368837   2.2050474    R3HDM1        hsa_circRNA_056558   chr2
  4.58024E‐05              0.010234685   2.1796815    NONO          hsa_circRNA_091000   chrX
  7.28006E‐06              0.004608971   2.081796     TMSB10        hsa_circRNA_055387   chr2
  1.63637E‐05              0.007501896   2.0692549    RHOA          hsa_circRNA_065649   chr3
  0.000308439              0.026756707   2.0369578    UBA52         hsa_circRNA_102488   chr19
  Downregulated circRNAs                                                                 
  0.000239906              0.023626342   2.6089515    EIF2S2        hsa_circRNA_402563   chr20
  0.000429469              0.030594986   2.4898771    NHS           hsa_circRNA_104983   chrX
  3.7363E‐07               0.002368837   2.3873504    CARHSP1       hsa_circRNA_037798   chr16
  0.000126081              0.018220113   2.2970696    MYH9          hsa_circRNA_400071   chr22
  0.000580943              0.035205611   2.2293785    SNX29         hsa_circRNA_405439   chr16
  0.000602971              0.035205611   2.1893188    FAM120A       hsa_circRNA_104826   chr9
  0.000801696              0.040069723   2.1390998    CNKSR3        hsa_circRNA_104230   chr6

circRNAs indicates circular RNAs; FC (abs), Fold change (absolute ratio); FDR, false discovery rate.

Hsa_circRNA_025016 Was Elevated in Patients With PoAF {#jah32831-sec-0021}
-----------------------------------------------------

The characteristics of the training and validation cohorts' participants are presented in Tables [5](#jah32831-tbl-0005){ref-type="table-wrap"} and [6](#jah32831-tbl-0006){ref-type="table-wrap"}. The 9 candidate circRNAs discovered in the microarray analyses were first tested with quantitative real‐time polymerase chain reaction using an independent cohort (training cohort) of 365 plasma samples. Six of the 9 circRNAs were stably detected in the plasma samples. Only 2 circRNAs---hsa_circRNA_025016 and hsa_circRNA_404686---were significantly upregulated and predicted PoAF in patients after CABG (odds ratio, 1.355 95% CI \[1.250--1.468\], *P*\<0.0001 and 1.098 95% CI \[1.009--1.195\], *P*=0.03, Figure [1](#jah32831-fig-0001){ref-type="fig"}C). Because the levels of hsa_circRNA_404686 were positively correlated with hsa_circRNA_025016 (Figure [1](#jah32831-fig-0001){ref-type="fig"}D), and hsa_circRNA_025016 exhibited the strongest association with PoAF, hsa_circRNA_025016 was selected for further analyses.

###### 

Demographic and Clinical Characteristics by Presence of PoAF in Training Cohorts (365)

  Characteristics                 PoAF Group n=75   No PoAF Group n=290   *P* Value
  ------------------------------- ----------------- --------------------- ----------------------------------------------
  Sex (male/female)               60/15             209/81                0.214
  Age, y                          63.55±8.05        61.86±8.56            0.112
  BMI, kg/m^2^                    25.23±2.41        24.68±2.88            0.166
  Smoking, %                      52 (69.3)         180 (62.2)            0.244
  Heart rate, beats/min           74.01±9.86        72.9±11.04            0.398
  NYHA III--IV, %                 11 (14.6)         40 (13.8)             0.139
  Hypertension, %                 49 (65.3)         190 (65.5)            0.152
  DM, %                           32 (42.6)         116 (40.0)            0.675
  Pre--myocardial infarction, %   45 (60.0)         140 (48.3)            0.009[a](#jah32831-note-0009){ref-type="fn"}
  Blood glucose, mmol/L           6.60±3.29         6.27±2.25             0.414
  Cholesterol, mmol/L             4.38±1.30         4.27±1.59             0.535
  Triglyceride, mmol/L            2.16±2.59         2.03±1.75             0.682
  LDL, mmol/L                     2.80±0.84         2.63±0.92             0.128
  HDL, mmol/L                     0.93±0.16         0.95±0.18             0.349
  Creatinine, μmol/L              73.01±12.59       73.28±16.13           0.876
  CKMB, U/L                       9.96±7.61         9.24±9.65             0.492
  cTNT, ng/mL                     0.10±0.44         0.07±0.47             0.605
  EF                              0.54±0.05         0.55±0.05             0.216
  LAD, mm                         38.01±4.24        36.96±4.23            0.063
  PASP, mm Hg                     35.18±3.43        34.18±4.47            0.128
  LVEDV, mL                       120.62±40.79      110.44±32.66          0.048[a](#jah32831-note-0009){ref-type="fn"}
  β‐Blockers, %                   68 (90.6)         270 (93.1)            0.472
  ACEI, %                         34 (45.3)         133 (45.8)            0.935
  CCB, %                          40 (53.3)         145 (50.0)            0.607
  Statins, %                      42 (56.0)         205 (70.7)            0.015[a](#jah32831-note-0009){ref-type="fn"}

Data presented as mean±SD or as a ratio. ACEI indicates angiotensin‐converting enzyme inhibitor; BMI, body mass index; CCB, calcium channel blocker; CKMB, creatine kinase MB; cTNT, cardiac troponin T; DM, diabetes mellitus; EF, ejection fraction; HDL, high‐density lipoprotein; LAD, left atrial diameter; LDL, low‐density lipoprotein; LVEDV, left ventricle end‐diastolic volume; NYHA, New York Heart Association; PASP, pulmonary arterial systolic pressure; PoAF, postoperative atrial fibrillation.

*P*\<0.05.

###### 

Demographic and Clinical Characteristics by Presence of PoAF in Validation Cohorts (284)

  Characteristics                 PoAF Group n=68   No PoAF Group n=216   *P* Value
  ------------------------------- ----------------- --------------------- ----------------------------------------------
  Sex (male/female)               55/13             159/57                0.225
  Age, y                          61.97±6.08        62.05±10.16           0.951
  BMI, kg/m^2^                    23.75±5.83        24.88±3.61            0.127
  Smoking, %                      42 (61.7)         128 (59.2)            0.713
  Heart rate, beats/min           76.43±11.72       74.32±9.84            0.113
  NYHA III--IV, %                 7 (10.2)          31 (14.3)             0.607
  Hypertension, %                 47 (69.1)         157 (72.6)            0.568
  DM, %                           22 (32.4)         80 (37.0)             0.483
  Pre--myocardial infarction, %   33 (48.5)         92 (42.5)             0.337
  Blood glucose, mmol/L           6.89±2.68         6.44±2.47             0.242
  Cholesterol, mmol/L             4.69±1.33         4.30±1.05             0.067
  Triglyceride, mmol/L            1.90±0.71         1.95±1.40             0.837
  LDL, mmol/L                     3.00±1.05         2.73±0.83             0.108
  HDL, mmol/L                     1.00±0.18         0.95±0.17             0.094
  Creatinine, μmol/L              77.37±17.52       79.40±20.37           0.469
  CKMB, U/L                       20.18±42.48       17.04±25.16           0.477
  cTNT, ng/mL                     0.28±1.24         0.23±0.86             0.679
  EF                              0.55±0.05         0.55±0.04             0.699
  LAD, mm                         38.12±4.49        36.73±4.79            0.081
  PASP, mm Hg                     34.53±9.73        33.72±5.79            0.489
  LVEDV, mL                       117.58±32.08      107.14±31.54          0.020[a](#jah32831-note-0012){ref-type="fn"}
  β‐Blockers, %                   62 (91.1)         204 (94.4)            0.335
  ACEI, %                         23 (33.8)         88 (40.7)             0.335
  CCB, %                          48 (70.0)         131 (60.6)            0.139
  Statins, %                      29 (42.6)         132 (61.1)            0.007[a](#jah32831-note-0012){ref-type="fn"}

Data presented as mean±SD or as a ratio. ACEI indicates angiotensin‐converting enzyme inhibitor; BMI, body mass index; CCB, calcium channel blocker; CKMB, creatine kinase MB; cTNT, cardiac troponin T; DM, diabetes mellitus; EF, ejection fraction; HDL, high‐density lipoprotein; LAD, left atrial diameter; LDL, low‐density lipoprotein; LVEDV, left ventricle end‐diastolic volume; NYHA, New York Heart Association; PASP, pulmonary arterial systolic pressure; PoAF, postoperative atrial fibrillation.

*P*\<0.05.

Next, we investigated the expression of hsa_circRNA_025016 in the training and validation cohorts. We found that hsa_circRNA_025016 was elevated in patients with coronary heart disease compared with the healthy controls. Additionally, an increase in the hsa_circRNA_025016 level was observed in patients with PoAF compared with those without PoAF (Figure [2](#jah32831-fig-0002){ref-type="fig"}A and [2](#jah32831-fig-0002){ref-type="fig"}B).

![Hsa_circRNA_025016 as a prognostic indicator of PoAF. A and B, Comparison of the hsa_circRNA_025016 levels in the healthy controls, patients with PoAF, and patients without PoAF in the training (A) and validation (B) cohorts. Unpaired Student *t* tests were used to determine the differences in hsa_circRNA_025016 levels between the groups (the error bars represent the SEM). PoAF indicates postoperative atrial fibrillation.](JAH3-7-e006642-g002){#jah32831-fig-0002}

Hsa_circRNA_025016 as a Prognostic Indicator for PoAF {#jah32831-sec-0022}
-----------------------------------------------------

The means and 95% CIs of the cutoff, sensitivity, and specificity were calculated via a 10‐fold cross‐validation method using the R package caret. The mean cutoff for 10 training data set was −12.118, and we considered this to be the optimum cutoff. The area under the receiver operating characteristic curve was 0.802, and the 95% confidence interval was 0.798 to 0.806. For the training data, the sensitivity was 0.794% (0.777--0.811%), and the specificity was 0.776% (0.763--0.789%); these results indicated a good predictive effect (Table [7](#jah32831-tbl-0007){ref-type="table-wrap"}).

###### 

Cutoff and Prediction Performance of hsa_circRNA_025016 in PoAF in Training Cohort (n=365)

                Training Data                Validation Data
  ------------- ---------------------------- ----------------------
  Cutoff        −12.118 (−12.334, −11.902)   ···
  AUC           0.802 (0.798, 0.806)         ···
  Sensitivity   0.794 (0.777, 0.811)         0.766 (0.644, 0.889)
  Specificity   0.776 (0.763, 0.789)         0.784 (0.749, 0.819)

AUC indicates area under the receiver operating characteristic curve; PoAF, postoperative atrial fibrillation.

The mean cutoff of −12.118 was used to evaluate the predictive effect in an independent validation cohort set (284 plasma samples). In the validation cohort, patients were divided into a high hsa_circRNA_025016 expression group and a low hsa_circRNA_025016 expression group according to the cutoff value. The predicted probability was evaluated with the χ^2^ test. This cutoff value was able to predict PoAF in the independent cohort (Pearson χ^2^=56.6, *P*\<0.0001, sensitivity=73.52% and specificity=77.83%, Table [8](#jah32831-tbl-0008){ref-type="table-wrap"}).

###### 

hsa_circRNA_025016 and PoAF in Validation Cohort (n=284)

            hsa_circRNA_025016   *P* Value   
  --------- -------------------- ----------- -------------------------------------------------
  PoAF      50                   18          \<0.0001[a](#jah32831-note-0015){ref-type="fn"}
  No PoAF   49                   167         

Sensitivity=73.52%, specificity=77.30%. PoAF indicates postoperative atrial fibrillation.

*P*\<0.0001.

Prediction and Annotation of the hsa_circRNA_025016 Targeted miRNA‐mRNA Network {#jah32831-sec-0023}
-------------------------------------------------------------------------------

We assumed that hsa_circRNA_025016 exerts its effects by acting as a miRNA sponge. The miRNA support vector regression algorithm was used to score and rank the efficiency of the predicted miRNA targets. Five miRNAs were identified as conserved between the TargetScan and miRanda predictions, including hsa‐miR‐6882‐3p, hsa‐miR‐4632‐5p, hsa‐miR‐3972, hsa‐miR‐4651, and hsa‐miR‐7974 (Figure [3](#jah32831-fig-0003){ref-type="fig"}). To explore the possible mechanism of hsa_circRNA_025016, Kyoto Encyclopedia of Genes and Genomes pathway analysis was utilized based on the predicted results. The results suggested that melanogenesis, insulin secretion, and the thyroid hormone signaling pathway may be modulated by hsa_circRNA_025016 (Figure [4](#jah32831-fig-0004){ref-type="fig"}A).

![Prediction of the miRNAs targeted by hsa_circRNA_025016.](JAH3-7-e006642-g003){#jah32831-fig-0003}

![Prediction and annotation of the targets of hsa_circRNA_025016 in the miRNA‐mRNA network. A, Kyoto Encyclopedia of Genes and Genomes analysis based on the hsa_circRNA_025016‐miRNA‐mRNAs network. B and C, The relationships between blood glucose and hsa_circRNA_025016 in the training (B) (*r*=0.2704, *P*\<0.0001) and validation cohorts (C) (*r*=0.2960, *P*\<0.0001).](JAH3-7-e006642-g004){#jah32831-fig-0004}

To explore the effect of hsa_circRNA_025016 on the insulin secretion pathway, the fasting blood glucose levels were compared according to the hsa_circRNA_025016 expression levels. As presented in Tables [9](#jah32831-tbl-0009){ref-type="table-wrap"} and [10](#jah32831-tbl-0010){ref-type="table-wrap"}, the fasting blood glucose levels were significantly higher in patients with high levels of hsa_circRNA_025016 expression in both cohorts. Moreover, hsa_circRNA_025016 exhibited significant linear correlations with fasting blood glucose in the training and validation cohorts (Figure [4](#jah32831-fig-0004){ref-type="fig"}B and [4](#jah32831-fig-0004){ref-type="fig"}C).

###### 

Demographic and Clinical Characteristics by the Expression of hsa_circRNA_025016 in Training Cohort (n=365)

  Characteristics                 hsa_circRNA_025016   *P* Value      
  ------------------------------- -------------------- -------------- ----------------------------------------------
  Sex (male/female)               90/33                179/63         0.870
  Age, y                          62.60±9.35           62.00±9.06     0.554
  BMI, kg/m^2^                    25.11±2.66           24.63±2.34     0.078
  Smoking, %                      79 (64.2)            153 (63.2)     0.850
  Heart rate, beats/min           73.91±10.99          72.7±10.07     0.294
  NYHA III--IV, %                 14 (11.4)            37 (15.2)      0.308
  Hypertension, %                 78 (63.4)            161 (66.5)     0.554
  DM, %                           48 (39.0)            101 (41.7)     0.618
  Pre--myocardial infarction, %   60 (48.7)            125 (51.6)     0.603
  Blood glucose, mmol/L           6.86±2.89            6.10±3.57      0.042[a](#jah32831-note-0018){ref-type="fn"}
  Cholesterol, mmol/L             4.45±1.49            4.20±1.78      0.182
  Triglyceride, mmol/L            2.19±2.28            1.99±2.58      0.456
  LDL, mmol/L                     2.76±0.99            2.61±0.96      0.164
  HDL, mmol/L                     0.96±0.28            0.93±0.18      0.216
  Creatinine, μmol/L              75.09±14.87          72.27±14.56    0.083
  CKMB, U/L                       9.87±7.71            9.14±9.46      0.459
  cTNT, ng/mL                     0.10±0.30            0.06±0.45      0.374
  EF                              0.55±0.05            0.54±0.06      0.873
  LAD, mm                         37.45±4.44           37.05±4.47     0.419
  PASP, mm Hg                     34.89±4.45           34.13±4.80     0.144
  LVEDV, mL                       115.54±35.21         111.00±43.99   0.321
  β‐Blockers, %                   116 (94.3)           222 (91.7)     0.374
  ACEI, %                         54 (43.9)            113 (46.7)     0.613
  CCB, %                          64 (52.0)            121 (50.0)     0.713
  Statins, %                      79 (64.2)            168 (69.4)     0.316

Data presented as mean±SD or as a ratio. ACEI indicates angiotensin converting enzyme inhibitor; BMI, body mass index; CCB, calcium channel blocker; CKMB, creatine kinase MB; cTNT, cardiac troponin T; DM, diabetes mellitus; EF, ejection fraction; HDL, high‐density lipoprotein; LAD, left atrial diameter; LDL, low‐density lipoprotein; LVEDV, left ventricle end‐diastolic volume; NYHA, New York Heart Association; PASP, pulmonary arterial systolic pressure.

*P*\<0.05.

###### 

Demographic and Clinical Characteristics by the Expression of hsa_circRNA_025016 in Validation Cohort (n=284)

  Characteristics                 hsa_circRNA_025016   *P* Value      
  ------------------------------- -------------------- -------------- ----------------------------------------------
  Sex (male/female)               77/22                137/48         0.487
  Age, y                          62.71±7.08           61.66±10.01    0.355
  BMI, kg/m^2^                    24.62±4.98           24.57±3.69     0.924
  Smoking, %                      56 (56.5)            114 (61.6)     0.407
  Heart rate, beats/min           75.17±10.65          74.64±11.05    0.697
  NYHA III--IV, %                 13 (13.1)            25 (13.5)      0.928
  Hypertension, %                 65 (66.6)            139 (75.1)     0.091
  DM, %                           36 (36.4)            66 (35.6)      0.908
  Pre--myocardial infarction, %   44 (44.4)            81 (43.7)      0.915
  Blood glucose, mmol/L           7.02±2.15            6.29±2.71      0.021[a](#jah32831-note-0021){ref-type="fn"}
  Cholesterol, mmol/L             4.53±1.25            4.31±1.02      0.111
  Triglyceride, mmol/L            2.09±1.24            1.83±0.77      0.052
  LDL, mmol/L                     2.89±0.904           2.73±0.781     0.127
  HDL, mmol/L                     0.99±0.17            0.95±0.18      0.070
  Creatinine, μmol/L              78.06±17.28          79.35±20.02    0.588
  CKMB, U/L                       18.87±38.76          17.25±25.38    0.712
  cTNT, ng/mL                     0.26±1.16            0.23±0.87      0.806
  EF                              0.55±0.05            0.55±0.03      0.690
  LAD, mm                         37.85±4.55           36.66±4.83     0.045[a](#jah32831-note-0021){ref-type="fn"}
  PASP, mm Hg                     33.98±5.76           33.84±7.02     0.865
  LVEDV, mL                       112.76±28.90         107.97±35.56   0.250
  β‐Blockers, %                   91 (91.9)            174 (94.0)     0.492
  ACEI, %                         32 (32.3)            79 (42.7)      0.087
  CCB, %                          62 (62.9)            117 (63.2)     0.918
  Statins, %                      49 (49.5)            112 (60.5)     0.073

Data presented as mean±SD or as a ratio. ACEI indicates angiotensin‐converting enzyme inhibitor; BMI, body mass index; CCB, calcium channel blocker; CKMB, creatine kinase MB; cTNT, cardiac troponin T; DM, diabetes mellitus; EF, ejection fraction; HDL, high‐density lipoprotein; LAD, left atrial diameter; LDL, low‐density lipoprotein; LVEDV, left ventricle end‐diastolic volume; NYHA, New York Heart Association; PASP, pulmonary arterial systolic pressure.

*P*\<0.05.

Discussion {#jah32831-sec-0024}
==========

PoAF is related to increased morbidity and mortality after cardiac surgery and is an independent risk factor for poor long‐term outcomes.[9](#jah32831-bib-0009){ref-type="ref"} However, poor understandings of the underlying mechanism and predisposing factors have limited the possible strategies for preventive preoperative measures. In the present study, we performed a wide screen to identify circRNAs that are differentially present in the plasma of patients with and without PoAF. Fifteen of the circRNAs were distinguished through hierarchical clustering analysis. When tested in the training cohort, at least 3 of these circRNAs candidates were found to be significantly upregulated in PoAF patients, and the strongest association was found for hsa_circRNA_025016. Surprisingly, the cutoff value for hsa_circRNA_025016 obtained from the training data resulted in high accuracy in the diagnosis of PoAF in the independent validation cohort set.

The study by Harling et al[7](#jah32831-bib-0007){ref-type="ref"} demonstrated that the levels of circulating and atrial tissue microRNAs are potential markers of PoAF. Other studies have found dysregulations of microRNAs in AF.[10](#jah32831-bib-0010){ref-type="ref"}, [11](#jah32831-bib-0011){ref-type="ref"} However, one of the main mechanisms of circRNAs is acting as inhibitors of miRNA that function by binding ("sponging") a specific miRNA. Furthermore, circRNAs are resistant to the exonuclease RNase R because of the lack of free ends; thus, circRNAs possess distinct advantages as new biomarkers for diagnoses, prognoses, and therapeutic response predictions. Moreover, circRNAs are a special class of noncoding RNAs that are abundant in body fluids. Therefore, we believe that circRNAs represent a class of highly stable biomarkers for the prediction of PoAF.

Hsa_circ_025016 was selected and further tested in 2 independent larger cohorts to demonstrate its high diagnostic value as a biomarker for PoAF. However, the mechanism of hsa_circ_025016 has not yet been demonstrated. To our surprise, the host gene symbol is calcium voltage‐gated channel subunit α1 C (CACNA1C), which encodes an α‐1 subunit of a voltage‐dependent calcium channel. Loss‐of‐function mutations in CACNA1C have been reported in short QT syndrome.[12](#jah32831-bib-0012){ref-type="ref"}

Another mechanism of circRNAs is acting as miRNA sponges and regulating the circRNA‐miRNA‐mRNA network. Therefore, we predicted the top 5 candidate miRNA binding targets according to the miRNA support vector regression scores and gained further insight into the functions of hsa_circ_025016. Kyoto Encyclopedia of Genes and Genomes pathway analysis was utilized based on the predicted results from the TargetScan and miRanda analyses. Interestingly, melanogenesis, insulin secretion, and the thyroid hormone signaling pathways were found to be the potentially affected pathways. Tatsuishi et al reported that blood glucose is a very strong predictor of PoAF after CABG.[13](#jah32831-bib-0013){ref-type="ref"} More importantly, we found that fasting blood glucose was increased in patients with high hsa_circ_025016 expression levels. Moreover, hsa_circ_025016 expression levels were positively correlated with fasting blood glucose in patients before surgery. These findings suggest that modulating insulin secretion may be one of the functions of hsa_circ_025016. Kirchhof et al[14](#jah32831-bib-0014){ref-type="ref"} found that the dysregulation of PITX2 expression could be responsible for susceptibility to AF. Expression array analyses have also suggested that melanogenesis is affected by the reduced expression of Pitx2c. Intriguingly, melanocyte‐like cells are present in mouse and human hearts that are predisposed to AF.[15](#jah32831-bib-0015){ref-type="ref"} Additionally, melanocortin can exert electrophysiological effects and stimulate the expression of interleukins.[16](#jah32831-bib-0016){ref-type="ref"} A recent review demonstrated that subclinical hyperthyroidism is associated with increased coronary heart disease events, mortality, and the incidence of AF.[17](#jah32831-bib-0017){ref-type="ref"}, [18](#jah32831-bib-0018){ref-type="ref"} Therefore, thyroid hormone may be another potential target that is affected by hsa_circ_025016. However, the underlying mechanisms by which hsa_circ_025016 regulates AF via affecting melanogenesis, insulin secretion, and the thyroid hormone signaling pathway need to be explored in future studies.

Conclusions {#jah32831-sec-0025}
===========

In conclusion, we found a plasma circRNA in a large number of participants that is unregulated in patients who developed PoAF when compared with non‐PoAF patients with a high degree of accuracy. Our study demonstrates that this plasma hsa_circ_025016 holds potential as a biomarker for the prediction of PoAF and could enable us to more accurately target patients who are at risk and thereby improve the effects of prophylactic treatments.
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